Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: Results from a randomized controlled trial

Journal of Drugs in Dermatology

Volumn 10, Issue 8, 2011, Pages 885-892

  Sofen, Howard ^a   Hudson, Charles P ^b   Cook Bolden, Fran E ^c   Preston, Norman ^d   Colón, Luz E ^d   Caveney, Scott W ^d   Gottschalk, Ronald W ^d  

^a Dermatology Research Associates   (United States)

^b Hudson Dermatology   (United States)

^c Research Division of the Skin Specialty Group   (United States)

^d Galderma Laboratories LP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOBETASOL PROPIONATE;

ADULT; APPLICATION SITE BURNING; APPLICATION SITE IRRITATION; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CUSHING SYNDROME; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FOLLICULITIS; GOBAL SEVERITY SCORE; HUMAN; MALE; MULTICENTER STUDY; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCALP; SKIN ATROPHY; SKIN PRURITUS; TELANGIECTASIA; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; ADULT; ANTI-INFLAMMATORY AGENTS; CLOBETASOL; CUSHING SYNDROME; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; SCALP; TREATMENT OUTCOME;

EID: 80053073371     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009;60:218-224.
2. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136-139. (Pubitemid 38457271)
3. Van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology. 1998;197:31-36. (Pubitemid 28327834)
4. Jarratt M, Breneman D, Gottlieb AB, et al. Clobetasol propionate shampoo 0.05%: a new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol. 2004;3:367-373.
5. Farber EM, Nall L. Natural history and treatment of scalp psoriasis. Cutis. 1992;49:396-400.
6. Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol. 2008;26:448-459.
7. Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60:962-971.
8. Feldman SR, Housman TS. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003;4:221-224. (Pubitemid 36506427)
9. Housman TS, Mellen BG, Rapp SR, et al. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference. Cutis. 2002;70:327-332. (Pubitemid 41757440)
10. Beutner K, Chakrabarty A, Lemke S, Yu K. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0.05% spray and its vehicle in the treatment of plaque psoriasis. J Drugs Dermatol. 2006;5:357-360.
11. Jarratt MT, Clark SD, Savin RC, et al. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaquetype psoriasis. Cutis. 2006;78:348-354. (Pubitemid 44952097)
12. Mraz S, Leonardi C, Colón LE, Johnson LA. Different treatment outcomes with different formulations of clobetasol propionate 0.05% for the treatment of plaque psoriasis. J Dermatolog Treat. 2008;19:354-359.
13. Menter A, Abramovits W, Colón LE, et al. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. J Drugs Dermatol. 2009;8:52-57.
14. Menter A. Topical monotherapy with clobetasol propionate spray 0.05% in the COBRA trial. Cutis. 2007;80(5 suppl):12-19.
15. Chen SC, Yeung J, Chren MM. Scalpdex: a quality-of-life instrument for scalp dermatitis. Arch Dermatol. 2002;138:803-807. (Pubitemid 34625526)
16. Reygagne P, Mrowietz U, Decroix J, et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatolog Treat. 2005;16:31-36. (Pubitemid 40283322)
17. Mazzotta A, Esposito M, Carboni I, Schipani C, Chimenti S. Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis. J Dermatolog Treat. 2007;18:84-87. (Pubitemid 46801840)
18. Olux Foam, 0.05% [package insert]. Research Triangle Park, NC: Stiefel Laboratories, Inc., a GSK Company; 2008.